%0 Journal Article %J Frontiers in Biotechnology and Bioengineering %D 2018 %T Biology of Vascular Endothelial Growth Factor C in the Morphogenesis of Lymphatic Vessels %A Khushbu Rauniyar %A Sawan K Jha %A Michael Jeltsch %K ADAMTS3 %K CCBE1 %K growth factor signaling %K growth factors %K Lymphatic Vessels %K lymphedema %K proteolytic processing %K Tissue Engineering %K VEGF receptors %K VEGF-C %X Because virtually all tissues contain blood vessels, the importance of hemevascularization has been long recognized in regenerative medicine and tissue engineering. However, the lymphatic vasculature has only recently become a subject of interest. Central to the task of growing a lymphatic network are lymphatic endothelial cells (LECs), which constitute the innermost layer of all lymphatic vessels. The central molecule that directs proliferation and migration of LECs during embryogenesis is Vascular Endothelial Growth Factor-C (VEGF-C). VEGF-C is, therefore, an important ingredient for LEC culture and attempts to (re)generate lymphatic vessels and networks. During its biosynthesis, VEGF-C undergoes a stepwise proteolytic processing, during which its properties and affinities for its interaction partners change. Many of these fundamental aspects of VEGF-C biosynthesis have only recently been uncovered. So far, most - if not all - applications of VEGF-C do not discriminate between different forms of VEGF-C. However, for lymphatic regeneration and engineering purposes, it appears mandatory to understand these differences, since they relate e.g. to such important aspects as biodistribution and receptor activation potential. In this review, we discuss the molecular biology of VEGF-C as it relates to the growth of LECs and lymphatic vessels. However, the properties of VEGF-C are similarly relevant for the cardiovascular system, since both old and recent data show that VEGF-C can have a profound effect on the blood vasculature. %B Frontiers in Biotechnology and Bioengineering %V 6 %8 02/2018 %G eng %U https://www.frontiersin.org/articles/10.3389/fbioe.2018.00007/full %9 review %R 10.3389/fbioe.2018.00007 %0 Journal Article %J Circulation %D 2013 %T Vascular endothelial growth factor-angiopoietin chimera with improved properties for therapeutic angiogenesis %A Andrey Anisimov %A Denis Tvorogov %A Annamari Alitalo %A Veli-Matti Leppänen %A Y An %A EC Han %A F Orsenigo %A EI Gaál %A Tanja Holopainen %A YJ Koh %A Tuomas Tammela %A P Korpisalo %A Salla Keskitalo %A Michael Jeltsch %A Seppo Ylä-Herttuala %A Elisabetta Dejana %A GY Koh %A C Choi %A Pipsa Saharinen %A Kari Alitalo %X BACKGROUND: There is an unmet need for proangiogenic therapeutic molecules for the treatment of tissue ischemia in cardiovascular diseases. However, major inducers of angiogenesis such as vascular endothelial growth factor (VEGF/VEGF-A) have side effects that limit their therapeutic utility in vivo, especially at high concentrations. Angiopoietin-1 has been considered to be a blood vessel stabilization factor that can inhibit the intrinsic property of VEGF to promote vessel leakiness. In this study, we have designed and tested the angiogenic properties of chimeric molecules consisting of receptor-binding parts of VEGF and angiopoietin-1. We aimed at combining the activities of both factors into 1 molecule for easy delivery and expression in target tissues. METHODS AND RESULTS: The VEGF-angiopoietin-1 (VA1) chimeric protein bound to both VEGF receptor-2 and Tie2 and induced the activation of both receptors. Detailed analysis of VA1 versus VEGF revealed differences in the kinetics of VEGF receptor-2 activation and endocytosis, downstream kinase activation, and VE-cadherin internalization. The delivery of a VA1 transgene into mouse skeletal muscle led to increased blood flow and enhanced angiogenesis. VA1 was also very efficient in rescuing ischemic limb perfusion. However, VA1 induced less plasma protein leakage and myeloid inflammatory cell recruitment than VEGF. Furthermore, angioma-like structures associated with VEGF expression were not observed with VA1. CONCLUSIONS: The VEGF-angiopoietin-1 chimera is a potent angiogenic factor that triggers a novel mode of VEGF receptor-2 activation, promoting less vessel leakiness, less tissue inflammation, and better perfusion in ischemic muscle than VEGF. These properties of VA1 make it an attractive therapeutic tool. %B Circulation %V 127 %P 424-434 %8 01/2013 %G eng %N 4 %& 424